WHO ICTRP trial
Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion…
JPRN-jRCT2031220390 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031220390 |
|---|---|
| Public title | Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations |
| Scientific title | Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR Exon 20 Insertion Mutations - BLU-451-1101 |
| Primary sponsor | Zalutskaya Alena |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Countries | US;Japan;Taiwan;Japan;South Korea;Japan;Canada;Japan |
| Conditions | Advanced cancer with EGFR Exon 20ins Mutations |
| Interventions | Determined dose of BLU-451 is orally administered BID or QD for each phase/cohort. |
| Registration date | Oct 18, 2022 |
| Target size | 15 |
| Secondary IDs | NCT05241873 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: